

[Artemether + lumefantrine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines](#) > [Medicines for curative treatment](#)

ATC codes: [P01BF01](#)

EMLc

Indication

Malaria due to Plasmodium vivax ICD11 code: [1F81](#)

INN

Artemether + lumefantrine

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid > dispersible tablet: 20 mg + 120 mg (EMLc)

Oral > Solid > tablet: 20 mg + 120 mg

EML status history

First added in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2009 ([TRS 958](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Artemether + lumefantrine](#)

DrugBank

[Artemether](#),

[Lumefantrine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to remove the footnotes describing a weight restriction and use during pregnancy, noting that use of this medicine should be in accordance with recommendations in WHO malaria guidelines.